Home » Business News » 2014 » March » March 21, 2014

Arseus in the Amsterdam Midcap Index

March 21, 2014 - London

Waregem (Belgium) / Rotterdam (The Netherlands)[1], 21 March 2014 - Arseus announced today that from 24 March 2014 the company would be included in the AMX Index. The Arseus share has been listed on Euronext Brussels and Amsterdam since 2007 and has been included in the Amsterdam Small Cap Index (AScX) since 2010. Arseus also got an option quotation on 16 December 2013.

The composition of the AMX Index is revised annually in March by Euronext Amsterdam based on the free-float market capitalisation of the listed companies. Arseus has a market capitalization of € 1.1 billion as of 20 March 2014.

Inclusion in the AMX Index will further boost the tradability and liquidity of the Arseus share, partly because the share now becomes interesting for institutional investors that only trade in the top 50 companies included in the NYSE Euronext AMX or AEX Index. 

Ger van Jeveren, CEO of Arseus: "Since the listing of Arseus on Euronext Brussels and Amsterdam in 2007, both the business and the share price have experienced strong growth. Arseus has developed rapidly into a purely scientific R&D business which provides innovative solutions and concepts to compounding pharmacies worldwide and total ICT solutions to medical professionals in Belgium, the Netherlands and France. The inclusion in the AMX Index is an important milestone for Arseus, it strengthens our investment profile and enhances our visibility on the financial markets, which will increase liquidity."

[1] This press release was sent out by Arseus NV and Arseus BV.

Please open the link below for the press release:

Arseus in the Amsterdam Midcap Index

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Arseus via Globenewswire



Comment on this story